Výsledky vyhledávání - "Jacqueline B. Krebs"

Phase II Trial of Topotecan Administered as a 21-Day Continuous Infusion in Previously Untreated Patients With Stage IIIB and IV Non-Small-Cell Lung Cancer

Autor: Stefan C. Grant, Graham A. Ross, Mark G. Kris, Hedy L. Kindler, Jacqueline B. Krebs, Vincent A. Miller, Ian E. Smith, Maurice L. Slevin

Publikováno v: American Journal of Clinical Oncology. 21:438-441

Topotecan (9-dimethylaminoethyl-10-hydroxycamptothecin) is a topoisomerase I inhibitor. Twenty-six patients with stage IIIB or IV non-small-cell lung cancer (NSCLC) who had received no prior chemotherapy were treated in a multicenter study with topot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44d602138a88dd1c795d2f8cff92af39
https://doi.org/10.1097/00000421-199810000-00003

Zobrazit plný text záznamu

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

Autor: Alan Gordon, Giorgio Bolis, Jacqueline B. Krebs, Andrea Lissoni, Scott Z. Fields, Henric Malmström, Michael A. Bookman

Publikováno v: Scopus-Elsevier

PURPOSE Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel. PATIENTS AND METHODS Topotec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7774b800171fd1a50431ccda7364f33
http://hdl.handle.net/10281/29415

Zobrazit plný text záznamu

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Autor: James Carmichael, Joan H. Schiller, J.P. Kleisbauer, Alain Depierre, P I Clark, Joachim von Pawel, Graham Ross, Nick G. Chrysson, S.Z. Fields, David J. Stewart, Stephen R. Lane, Richard J. Gralla, Martin Palmer, Jacqueline B. Krebs, Frances A. Shepherd

Publikováno v: Journal of Clinical Oncology. 17:658-658

PURPOSE: Topotecan and cyclophosphamide, doxorubicin, and vincristine (CAV) were evaluated in a randomized, multicenter study of patients with small-cell lung cancer (SCLC) who had relapsed at least 60 days after completion of first-line therapy. PAT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342a1ed4c2e5fd267292e284b4cf0e2b
https://doi.org/10.1200/jco.1999.17.2.658

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání